Dicerna Pharmaceuticals

Dicerna Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. Dicerna’s entire drug pipeline is generated from its proprietary RNA interference (RNAi) technology platform, which is believed to improve upon existing RNAi technologies. RNAi is a highly potent and specific mechanism for silencing the activity of a targeted disease-driving gene. Dicerna’s discovery approach is based on proprietary double-stranded RNA molecules which the Company believes maximizes RNAi potency.
Company Growth (employees)
Cambridge, US
Size (employees)
47 (est)
Dicerna Pharmaceuticals was founded in 2007 and is headquartered in Cambridge, US

Key People/Management at Dicerna Pharmaceuticals

Douglas Fambrough

Douglas Fambrough

Bob D. Brown

Bob D. Brown


Dicerna Pharmaceuticals Office Locations

Dicerna Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
87 Cambridge Park Dr
Show all (1)

Dicerna Pharmaceuticals Financials and Metrics

Dicerna Pharmaceuticals Financials

Dicerna Pharmaceuticals's revenue was reported to be $295 k in FY, 2016

Revenue (Q3, 2017)

474 k

Net income (Q3, 2017)

(15 m)

EBIT (Q3, 2017)

(15.2 m)

Market capitalization (16-Feb-2018)

220.3 m

Cash (30-Sep-2017)

31 m
Dicerna Pharmaceuticals's current market capitalization is $220.3 m.
USDFY, 2014FY, 2015FY, 2016


184 k295 k

Revenue growth, %


R&D expense

29.5 m44 m41.7 m

General and administrative expense

15.6 m19.2 m18.3 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


184 k184 k184 k162 k133 k252 k474 k

R&D expense

5.3 m6.8 m7.5 m8.7 m11.9 m12.1 m11.3 m11 m10.1 m8.9 m9.3 m9 m

General and administrative expense

2.8 m4.4 m3.7 m5.4 m4.5 m4.9 m4.5 m4.7 m4.3 m5.5 m6.3 m6.7 m

Operating expense total

8.1 m11.2 m11.2 m14.1 m16.4 m17 m15.7 m15.7 m14.4 m14.4 m15.6 m15.7 m
USDFY, 2014FY, 2015FY, 2016


26.1 m56.1 m20.9 m

Accounts Receivable

254.7 m805.4 k


1.2 m1.5 m2 m

Current Assets

97.3 m96.1 m47.8 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


133.8 m77.7 m31.8 m22.6 m25.9 m52.9 m27.6 m29.2 m32.5 m22.9 m38.8 m31 m

Current Assets

134.7 m101.3 m93.7 m89.1 m96.7 m95.7 m81.8 m70.7 m59.4 m36.2 m91.7 m79.8 m


911 k1.5 m1.9 m2.3 m2.6 m2.7 m2.5 m2.5 m2.4 m2 m1.8 m1.7 m

Total Assets

135.9 m124.2 m116 m92.7 m127.7 m113.6 m85.5 m74.3 m62.9 m39.4 m94.7 m82.7 m
USDFY, 2014FY, 2015FY, 2016

Net Income

(47.9 m)(62.8 m)(59.5 m)

Depreciation and Amortization

848 k727 k840 k

Accounts Receivable

(15.1 m)


(44.3 m)
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(10.8 m)(11.4 m)(11.2 m)(14.1 m)(16.2 m)(16.9 m)(15.7 m)(15.6 m)(14.2 m)(14.2 m)

Depreciation and Amortization

164 k

Accounts Payable

1.1 m1.2 m525 k1.6 m1.4 m2.4 m3.2 m3.7 m4.1 m

Cash From Operating Activities

(10.6 m)
USDY, 2017


10.1 k
Show all financial metrics

Dicerna Pharmaceuticals Market Value History

Dicerna Pharmaceuticals's Web-traffic and Trends

Dicerna Pharmaceuticals Online and Social Media Presence

Dicerna Pharmaceuticals Company Life and Culture

You may also be interested in